The continued selloff is most likely because of what is already known to the market:
- McPhilly's is likely going to be dead on arrival, capex figure far too burdensome (especially given RRL's existing debt)
- With their long-promoted growth project likely gone, they're now having to pump Duketon North/South and Rosemont as "Underground Growth" whereas in reality it's just replacing depleted ounces.
- The announcement didn't give any specifics and just ambiguously claimed that the spend would be "value accretive across a range of prices". This from the same management team who decided to wait until gold was hitting fresh ATH's before closing out their hedge book at a cost of $98M - not sure they understand what "value" looks like
It's no surprise to me that since 1st May, short positions have increased from 1.22% up to 3.27%. If you wanted to hedge your long-gold positions elsewhere with a sector underperformer, Regis is where you come.
- Forums
- ASX - By Stock
- RRL
- Ann: Becoming a substantial holder
RRL
regis resources limited
Add to My Watchlist
1.54%
!
$4.49

Ann: Becoming a substantial holder, page-29
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$4.49 |
Change
-0.070(1.54%) |
Mkt cap ! $3.392B |
Open | High | Low | Value | Volume |
$4.54 | $4.54 | $4.45 | $14.40M | 3.212M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2269 | $4.48 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.50 | 55705 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 44961 | 4.450 |
3 | 33384 | 4.440 |
2 | 20784 | 4.430 |
1 | 2272 | 4.400 |
1 | 500 | 4.390 |
Price($) | Vol. | No. |
---|---|---|
4.500 | 55705 | 3 |
4.510 | 28718 | 2 |
4.520 | 16651 | 2 |
4.550 | 1000 | 1 |
4.580 | 6000 | 1 |
Last trade - 16.12pm 26/06/2025 (20 minute delay) ? |
Featured News
RRL (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online